Delivery Order SPE2DR25D3111-SPE2DR26FF3FA
- Not listed
- The Defense Logistics Agency awarded a $1,967.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injectors on August 13, 2025, with completion targeted for August 14, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,069.43 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections in a firm fixed-price arrangement valued at $1,374.76, with an ultimate completion date of August 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections, valued at $2,720.90 with a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of September 29, 2025, issued on September 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $2,468.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections on August 12, 2025, with an ultimate completion date of August 13, 2025. This is an unset-aside, competitively awarded contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $3,265.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injections. The contract, with an ultimate completion date of November 3, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen's Conshohocken, Pennsylvania facility serves as the place of performance. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $17,895.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 ml pen injectors (0.5 ml), with an ultimate completion date of October 24, 2025. This non-set-aside contract was competitively awarded and represents a direct delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $10,883.60 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on September 24, 2025, with completion targeted for September 25, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $4,541.93 to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections on April 24, 2025, with completion expected by April 25, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded pharmaceutical supply under the company's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $54,938.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Mounjaro 2.5 mg/0.5 ml pen injections. This non-set-aside contract is categorized as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- SPE2DR25D3111Indefinite Delivery Contract
- SPE2DR25D3111-SPE2DR26FF3FADelivery Order
The Defense Logistics Agency awarded a $2,412.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 mL pen injections on November 14, 2025, with completion targeted for November 17, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control and weight management in patients with type 2 diabetes. This delivery order exemplifies AmerisourceBergen's critical role as a pharmaceutical prime vendor for the federal medical supply chain, supporting military healthcare programs and the Defense Health Agency. The company's comprehensive IDC vehicle enables it to fulfill varied pharmaceutical procurement needs across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies, demonstrating its established capacity to meet federal healthcare system requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 11/14/25 |